Bedside Assessment of Coagulation in Post-partum Hemorrhage by Thromboelastography (TEG ®6S)

Post Partum Hemorrhage Clinical Trial

— HPPTEG6S  

Official title:

Bedside Assessment of Coagulation in Post-partum Hemorrhage by Thromboelastography (TEG ®6S)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03592303
• Other study ID #: NI17042J
• Secondary ID: 2017-A02347-46
• Status: Not yet recruiting
• Start date: August 2018
• Est. completion date: March 2019

Study information

• Verified date: May 2018
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: Agnès Rigouzzo
• Phone: +33171738969
• Email: agnes.rigouzzo[@]aphp.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Postpartum hemorrhage (PPH) is one of the leading causes of maternal deaths. Its prognosis is directly influenced by the early diagnosis and treatment of the associated coagulopathy. In this context, fibrinogen concentration is the best predictor of a severe PPH. The medical interest of thromboelastography/elastometry to early detect and guide the rapid correction of coagulopathy in PPH is regularly discussed.

The principal aim of this study is to evaluate the performance of a new hemostasis point of care device (thromboelastography - TEG ®6S) for the diagnosis of coagulopathy during PPH.

A secondary aim will be to determine the normal values of TEG6S at the end of a normal pregnancy.

Description:

Postpartum hemorrhage (PPH) is a complication of 5 to 10% of deliveries and is the leading cause of maternal mortality, all over the world. In France, as in other developed countries, 20% of maternal mortality is related to PPH complications with a high rate of avoidance (85%) due to inappropriate or delayed therapeutic measures). The management of PPH is based on recommendations highlighting the need for early detection and treatment of coagulopathy, which is predictive of the hemorrhage severity. The prognosis of the PPH is directly related to the rapidity of the coagulopathy treatment (30 to 60 minutes after diagnosis). Severe PPH is often associated with clotting disorders of either primary origin (disseminated intravascular coagulation) or secondary origin (coagulation factors loss due to hemorrhage). A hypofibrinogenemia < 2 g/L is the best predictor of a severe PPH with a positive predictive value of 100% . Similarly, abnormal coagulation tests appear to be predictive of the severity of the bleeding and the subsequent need for invasive procedures.

The assessment of coagulation is currently based on standard laboratory hemostasis tests, but with delayed time to obtain results, generally greater than 60 minutes. Therefore, early and fast assessment of hemostasis during PPH is essential to estimate the bleeding severity and allow early and adequate administration of pro-coagulant products, leading to an improved prognosis of PPH. The medical interest of thromboelastography (TEG) to early diagnose and guide the treatment of a coagulopathy in PPH is regularly discussed.

A previous observational study performed by our team in 2013 during PPH (95 patients and133 samples) compared the TEG 5000 parameters with the standard laboratory hemostasis tests. Our results confirm the good predictability of TEG 5000 for the early detection of a hypofibrinogenemia ≤ 2 g / l and/or thrombocytopenia ≤ 80 000 platelets / mm3 (AUC between 0.91 and 0.97). Among the biological parameters analyzed by the TEG 5000, the parameters K-MRTGG and FF-MRTGG (maximum rate of thrombus generation) were also evaluated. Their predictabilities were as good as the usual K-MA or FF-MA (comparable AUC) and were available more rapidly than usual parameters (3 ± 3 min for FF-MRTGG and 8 ± 3 min for K-MRTGG), allowing a very early evaluation of hemostasis.

The aim of this prospective observational study is therefore to evaluate the performance of a new delocalized hemostasis monitoring device (thromboelastography - TEG ®6S) for the diagnosis of coagulopathy during PPH.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 100
• Est. completion date: March 2019
• Est. primary completion date: August 2018
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18 years old

• Patient with health insurance

• Group of patients during labor : any pregnant woman with a normal pregnancy in the delivery room.

• Group of patients with PPH: any woman with a normal pregnancy experiencing a PPH with blood loss greater than 500 mL and who requires a biological evaluation of haemostasis.

Exclusion Criteria:

• Coagulopathy pre-existing to pregnancy

• Medication that interferes with blood coagulation

• Hepato-cellular insufficiency

• Renal failure

• Psychiatric care patients

• Patient deprived of liberty by judicial or administrative decision

• Major patient undergoing legal protective measures

Related Conditions & MeSH terms

• Blood Coagulation Disorders
• Blood Protein Disorders
• Coagulation Defect; Puerperal
• Hemorrhage
• Hemostatic Disorders
• Post Partum Hemorrhage
• Postpartum Hemorrhage
• Pregnancy Hemorrhage

Locations

Country	Name	City	State
France	Hopital Trousseau	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Performance analysis of TEG6S kaolin parameters for the diagnosis of coagulation disorders in PPH.	The performance analysis of the parameters derived from the Kaolin test will be performed using ROC curves and a sensitivity and specificity calculation.	during the 24 hours after delivery
Secondary	Performance analysis of TEG6S RapidTEG parameters for the diagnosis of coagulation disorders in PPH.	The performance analysis of the parameters derived from the RapidTEG test will be performed using ROC curves and a sensitivity and specificity calculation.	during the 24 hours after delivery.
Secondary	Performance analysis of TEG6S Functional Fibrinogen parameters for the diagnosis of coagulation disorders in PPH.	The performance analysis of the parameters derived from Functional Fibrinogen test will be performed using ROC curves and a sensitivity and specificity calculation.	during the 24 hours after delivery.
Secondary	Analysis of the correlation between the parameters provided by TEG6S and standard laboratory tests.	Analysis of correlation between the parameters of CFF test and laboratory tests.	during the 24 hours after delivery.
Secondary	Analysis of the correlation between the parameters provided by TEG6S and standard laboratory tests.standard laboratory tests.	analysis of correlation between the parameters of CK test and laboratory tests.	during the 24 hours after delivery.
Secondary	Analysis of the correlation between the parameters provided by TEG6S and standard laboratory tests.	analysis of correlation between the parameters of CRT test and laboratory tests.	during the 24 hours after delivery.
Secondary	Performance of TEG6S parameters for predicting severe HPP	Blood loss will be calculated 24 hours after delivery, based on demographic data and hematocrit (Ht) values measured in the last month of pregnancy and 24 hours after delivery.	24 hours after delivery.
Secondary	Comparison of the time taken to obtain the different TEG6S parameters versus standard biology parameters.	The time taken to obtain the TEG6S parameter CK-MA will be measured. It corresponds to the time between the start of the analysis (including the start of the test) and the time the result is provided by the TEG6S.	during 24 hours after delivery
Secondary	Comparison of the time taken to obtain the different TEG6S parameters versus standard biology parameters.	The time taken to obtain the TEG6S parameter CRT-MA will be measured. It corresponds to the time between the start of the analysis (including the start of the test) and the time the result is provided by the TEG6S.	during 24 hours after delivery
Secondary	Comparison of the time taken to obtain the different TEG6S parameters versus standard biology parameters.	The time taken to obtain the TEG6S parameter FF-MA will be measured. It corresponds to the time between the start of the analysis (including the start of the test) and the time the result is provided by the TEG6S.	during 24 hours after delivery
Secondary	Define normal reference values for TEG6S Thromboelastography in pregnant women during labor.	2.9 mL of additional blood will be collected for TEG6S analysis.	during 24 hours after delivery